Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5514446 | PMC |
| http://dx.doi.org/10.1128/MCB.00212-17 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Parental and Medical Classification of Neurodevelopment in Children Born Preterm.
Pediatrics
January 2025
Department of Pediatrics, University of British Columbia, Vancouver, British Columbia, Canada.
Background And Objectives: The likelihood and severity of neurodevelopmental impairment (NDI) affects critical health care decisions. NDI definitions were developed without parental perspectives. We investigated the agreement between parental vs medical classification of NDI among children born preterm.
View Article and Find Full Text PDFBackground: Changes in Amyloid-β (A) and hyperphosphorylated Tau (T) in the brain and cerebrospinal fluid (CSF) precedes AD symptoms, making the CSF proteome a potential avenue to understand disease pathophysiology and facilitate reliable diagnostics and therapies.
Method: We used the Somascan assay for measuring the protein levels of 7,029 analytes in CSF of 2,286 participants from four different cohorts. We employed a three-stage analytical approach (discovery, replication, and meta-analysis).
Biomarkers.
Alzheimers Dement
December 2024
NeuroGenomics & Informatics Center, Washington University School of Medicine, St. Louis, MO, USA.
Background: Brain, cerebrospinal fluid (CSF), and plasma metabolomics have been informative in identifying disrupted metabolism pathways in Alzheimer's disease (AD). However, many AD-focused metabolomics studies profiled a relatively small number of individuals and metabolites, especially for CSF. In addition, past studies were limited to one or two tissues.
View Article and Find Full Text PDFBackground: Renal atrophy may reflect an end organ consequence of chronic vascular disease. Renal volume loss may therefore provide a window into brain aging and Alzheimer disease risk.
Method: We obtained whole-body 1.
Biomarkers.
Alzheimers Dement
December 2024
Pacific Brain Health Center, Pacific Neuroscience Institute and Foundation, Santa Monica, CA, USA.
Background: AD-NeuroScore is a validated metric that summarizes Alzheimer's disease (AD)-specific atrophy and can detect AD early, benchmark disease severity, predict and monitor AD progression, and can aid in testing the efficacy of therapeutic interventions using a single number (Kress, 2023). It meets criteria for translatability by using clinically available regional brain volumes as input (Ahdidan, 2015; Cavedo, 2022) and having patient and model-level interpretability (Pinto, 2022). Also, features can be reviewed by a neuroradiologist (Larson, 2019).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!